Scribe Therapeutics Funding: $120M Raised, Series A (2018)
Scribe Therapeutics is based in Berkeley, California. It has raised $120M in total funding. Latest round: Series A. Backed by Andreessen Horowitz.
Scribe Therapeutics funding overview
Scribe Therapeutics is based in Berkeley, California. Scribe Therapeutics has raised $120M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in January 2018. The round record for Scribe Therapeutics runs through 2018; nothing later has been disclosed. Investors on record include Andreessen Horowitz.
Scribe Therapeutics at a glance
Total raised
$120M
Latest round
Series A
Latest round date
January 2018
Headquarters
Berkeley, California
Notable investors
Andreessen Horowitz
Frequently asked about Scribe Therapeutics funding
How much has Scribe Therapeutics raised?
Scribe Therapeutics has raised $120M in total disclosed funding across the rounds on record.
Who has invested in Scribe Therapeutics?
Andreessen Horowitz are named among the investors backing Scribe Therapeutics.
What was the latest Scribe Therapeutics funding round?
The most recent disclosed round is a Series A, announced in January 2018.
Where is Scribe Therapeutics based?
Scribe Therapeutics is based in Berkeley, California.
When did Scribe Therapeutics last raise?
The last disclosed Scribe Therapeutics round closed in January 2018 at Series A.
Totals shown for Scribe Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Berkeley and the investors behind them below.
